Sirnaomics Closes $105 Million Funding for RNAi Portfolio

Sirnaomics, a Mayland-Suzhou biopharma developing RNAi therapies, closed a $105 million Series E. The company is developing novel RNAi therapeutics that treat cancer, fibrosis diseases, metabolic diseases and viral infections. Sirnaomics' two lead candidates, STP705 and STP707, are dual targeting siRNA therapeutics against TGF-β1 and COX-2 for both local and systemic administration for cancer and fibrotic diseases. The E round was co-led by long-time investor Rotating Boulder Fund of China , plus new new investors Walvax Biotech and Sunshine Riverhead Capital. More details.... Share this with colleagues: // //